562 related articles for article (PubMed ID: 32988222)
1. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
Qi Z; Hu L; Zhang J; Yang W; Liu X; Jia D; Yao Z; Chang L; Pan G; Zhong H; Luo X; Yao K; Sun A; Qian J; Ding Z; Ge J
Circulation; 2021 Jan; 143(1):45-61. PubMed ID: 32988222
[TBL] [Abstract][Full Text] [Related]
2. IL-37 Attenuates Platelet Activation and Thrombosis Through IL-1R8 Pathway.
Chen Y; Hong J; Zhong H; Zhao Y; Li J; Shen W; Luo X; Shi H; Hu L; Liu J; Gao W
Circ Res; 2023 Apr; 132(9):e134-e150. PubMed ID: 36999436
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
Paciullo F; Momi S; Gresele P
Thromb Haemost; 2019 Mar; 119(3):359-367. PubMed ID: 30605918
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 Biology and Its Role in Atherothrombosis.
Barale C; Melchionda E; Morotti A; Russo I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
[TBL] [Abstract][Full Text] [Related]
5. Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis.
Zhang S; Zhang S; Hu L; Zhai L; Xue R; Ye J; Chen L; Cheng G; Mruk J; Kunapuli SP; Ding Z
Circulation; 2015 Mar; 131(13):1160-70. PubMed ID: 25825396
[TBL] [Abstract][Full Text] [Related]
6. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up.
Barale C; Bonomo K; Frascaroli C; Morotti A; Guerrasio A; Cavalot F; Russo I
Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):282-291. PubMed ID: 31653513
[TBL] [Abstract][Full Text] [Related]
7. Platelet CD36 signaling through ERK5 promotes caspase-dependent procoagulant activity and fibrin deposition in vivo.
Yang M; Kholmukhamedov A; Schulte ML; Cooley BC; Scoggins NO; Wood JP; Cameron SJ; Morrell CN; Jobe SM; Silverstein RL
Blood Adv; 2018 Nov; 2(21):2848-2861. PubMed ID: 30381401
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
Demers A; Samami S; Lauzier B; Des Rosiers C; Ngo Sock ET; Ong H; Mayer G
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2517-25. PubMed ID: 26494228
[TBL] [Abstract][Full Text] [Related]
9. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
10. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
[No Abstract] [Full Text] [Related]
11. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein.
Chen K; Febbraio M; Li W; Silverstein RL
Circ Res; 2008 Jun; 102(12):1512-9. PubMed ID: 18497330
[TBL] [Abstract][Full Text] [Related]
12. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
13. Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection.
Zhang X; Xu H; Yu J; Cui J; Chen Z; Li Y; Niu Y; Wang S; Ran S; Zou Y; Wu J; Xia J
Circulation; 2023 Jul; 148(4):336-353. PubMed ID: 37232170
[TBL] [Abstract][Full Text] [Related]
14. Exosome poly-ubiquitin inhibits platelet activation, downregulates CD36 and inhibits pro-atherothombotic cellular functions.
Srikanthan S; Li W; Silverstein RL; McIntyre TM
J Thromb Haemost; 2014 Nov; 12(11):1906-17. PubMed ID: 25163645
[TBL] [Abstract][Full Text] [Related]
15. Modulation of human platelet activation and in vivo vascular thrombosis by columbianadin: regulation by integrin α
Hou SM; Hsia CW; Tsai CL; Hsia CH; Jayakumar T; Velusamy M; Sheu JR
J Biomed Sci; 2020 May; 27(1):60. PubMed ID: 32375785
[TBL] [Abstract][Full Text] [Related]
16. Tetrahydrocurcumin Downregulates MAPKs/cPLA2 Signaling and Attenuates Platelet Thromboxane A2 Generation, Granule Secretion, and Thrombus Growth.
Li W; Ma Y; Zhang C; Chen B; Zhang X; Yu X; Shuai H; He Q; Ya F
Thromb Haemost; 2022 May; 122(5):739-754. PubMed ID: 34428833
[TBL] [Abstract][Full Text] [Related]
17. Correction to: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
Circulation; 2021 Jan; 143(1):e4. PubMed ID: 33378240
[No Abstract] [Full Text] [Related]
18. Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction.
Nakamura A; Kanazawa M; Kagaya Y; Kondo M; Sato K; Endo H; Nozaki E
J Cardiol; 2020 Oct; 76(4):395-401. PubMed ID: 32439340
[TBL] [Abstract][Full Text] [Related]
19. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice.
Ghosh A; Li W; Febbraio M; Espinola RG; McCrae KR; Cockrell E; Silverstein RL
J Clin Invest; 2008 May; 118(5):1934-43. PubMed ID: 18431509
[TBL] [Abstract][Full Text] [Related]
20. Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling.
Irfan M; Jeong D; Kwon HW; Shin JH; Park SJ; Kwak D; Kim TH; Lee DH; Park HJ; Rhee MH
Vascul Pharmacol; 2018 Oct; 109():45-55. PubMed ID: 29890296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
